8. Lease Agreements

XOMA Royalty Office Lease

The Company leases a facility in Emeryville, California under an operating lease, which commenced on November 10, 2023 and has a term of 65 months. The Company recognized an operating lease right-of-use assets of $0.4 million and operating lease liabilities of $0.4 million on November 10, 2023, the commencement date of the lease.

Leases Assumed in Acquisitions

Kinnate Lease and Sublease

As part of the Kinnate acquisition, the Company acquired a lease agreement that was assigned to an assignee and expires on June 30, 2026. In accordance with ASC 842, the Company accounted for the lease as if it had commenced on the acquisition date. The Company recognized operating lease liabilities of $0.8 million as of April 3, 2024. No operating lease right-of-use assets were recorded due to the allocation of the excess of fair value of net assets acquired to certain qualifying assets under ASC 805.

As part of the Kinnate acquisition, the Company acquired a lease assignment agreement with an assignee that expires on June 30, 2026. For the three and nine months ended September 30, 2025, the Company recognized sublease income of $0.1 million and $0.3 million, respectively, in the other income, net line item in the condensed consolidated statement of operations. For the three and nine months ended September 30, 2024, the Company recognized sublease income of $0.1 million and $0.2 million in the other income, net line item in the condensed consolidated statement of operations.

Turnstone Lease and Sublease

As part of the Turnstone acquisition, the Company acquired an immaterial short-term lease agreement and a related sublease agreement that expires in February 2026.

HilleVax - Boston Lease

As part of the HilleVax acquisition, the Company acquired the Boston Lease that expires on December 31, 2032. In accordance with ASC 842, the Company accounted for the lease as if it had commenced on the acquisition date. The Company recognized operating lease liabilities of $22.4 million as of September 17, 2025. No operating lease right-of-use assets were recorded due to the allocation of the excess of fair value of net assets acquired to certain qualifying assets under ASC 805. The lease includes a single option to extend the term for an additional five years following the initial 10-year term, which the Company is not reasonably certain to exercise.

HilleVax - Swiss Lease

As part of the HilleVax acquisition, the Company acquired the Swiss Lease that expires on September 30, 2026. In accordance with ASC 842, the Company accounted for the lease as if it had commenced on the acquisition date. The Company recognized operating lease liabilities of $0.1 million as of September 17, 2025. No operating lease right-of-use assets were recorded due to the allocation of the excess of fair value of net assets acquired to certain qualifying assets under ASC 805.

HilleVax Sublease

As part of the HilleVax acquisition, the Company acquired an executed sublease agreement with a sublessee for a portion of the Boston Lease premises. The sublease commences on the later of (i) the date consent from the landlord is obtained and delivered to the sublessee, (ii) November 1, 2025, and (iii) two weeks after the date HilleVax delivers possession of the premises to the sublessee in the required condition. The sublease expires three years and two months following the commencement date. As the sublease has not yet commenced as of September 30, 2025, no sublease income has been recognized for the three and nine months ended September 30, 2025.

The following table summarizes the maturity of the Company’s operating lease liabilities as of September 30, 2025 (in thousands):

​

As of September 30, 2025 and December 31, 2024, the total net lease liability was $23.2 million and $0.9 million, respectively.

As of September 30, 2025, the Company’s current and non-current operating lease liabilities were $2.5 million and $20.7 million, respectively.

As of December 31, 2024, the Company’s current and non-current operating lease liabilities were $0.4 million and $0.5 million, respectively.

The following table summarizes the cost components of the Company’s operating leases included in G&A in the condensed consolidated statements of operations for the three and nine months ended September 30, 2025 and 2024 (in thousands):

​

​

​

The following table presents supplemental disclosure for the condensed consolidated statements of cash flows related to operating leases (in thousands):

​

​

The assumptions used in calculating the present value of the lease payments for the Company’s operating leases as of September 30, 2025 and December 31, 2024 were as follows:

​

​